Benjamin Edwards Inc. Cuts Stake in Zoetis Inc. $ZTS

Benjamin Edwards Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 61.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 88,566 shares of the company's stock after selling 142,600 shares during the quarter. Benjamin Edwards Inc.'s holdings in Zoetis were worth $6,364,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. J. Stern & Co. LLP raised its holdings in Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares in the last quarter. Norges Bank purchased a new position in Zoetis during the fourth quarter valued at $734,425,000. Flossbach Von Storch SE bought a new stake in shares of Zoetis during the 2nd quarter valued at $302,601,000. BlackRock Inc. grew its position in shares of Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock worth $2,833,453,000 after buying an additional 3,845,869 shares during the period. Finally, Ruane Cunniff & Goldfarb L.P. purchased a new stake in shares of Zoetis in the 1st quarter worth about $286,660,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of recent research reports. BNP Paribas Exane cut their price objective on shares of Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a report on Tuesday, August 11th. William Blair reissued a "market perform" rating on shares of Zoetis in a research report on Thursday, August 6th. Stifel Nicolaus cut their price target on Zoetis from $85.00 to $80.00 and set a "hold" rating on the stock in a research note on Thursday, August 20th. TD Cowen reduced their price objective on Zoetis from $104.00 to $94.00 and set a "buy" rating for the company in a research report on Tuesday, August 25th. Finally, Cantor Fitzgerald set a $94.00 price objective on Zoetis in a research note on Tuesday, August 25th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $107.43.

Zoetis Stock Up 0.1%

ZTS stock opened at $77.45 on Monday. The stock has a market capitalization of $32.00 billion, a P/E ratio of 12.76, a P/E/G ratio of 1.80 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $156.49. The business has a fifty day moving average price of $75.57 and a 200-day moving average price of $95.40.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion for the quarter, compared to analysts' expectations of $2.50 billion. During the same period last year, the firm posted $1.76 earnings per share. Zoetis's revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source